Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
StandardAero Q1 2026 Earnings Call - Raised Full-Year Guidance Amid Strong Demand Across All End Markets
StandardAero delivered a robust start to 2026, reporting 13.3% organic revenue growth and raising full-year guidance for revenue, adjusted EBITDA, and adjusted EPS. The company benefited from double-d...
- Organic revenue grew 13.3% year-over-year to $1.63 billion, driven by double-digit growth across commercial aerospace (up 11%), business aviation (up 20%), and military/helicopter (up 10%).
- Adjusted EBITDA increased 2.5% to $203 million, but underlying growth was double-digit and margins exceeded 14% when excluding transitory items like the LEAP/CFM56 ramp, inventory burndown, and a one-time military contract closeout cost.
- Adjusted EPS rose 14% to $0.33, reflecting higher operating earnings and lower interest expense.
- +7 more takeaways
Yelp Inc. Q1 2026 Earnings Call - AI-Driven 'Other Revenue' Surges 75% as Core Ads Stagnate
Yelp’s Q1 2026 results highlight a company in transition. Core advertising revenue remained flat to down as local businesses face persistent economic headwinds, with services ads up just 1% and RR&O a...
- Net revenue grew 1% YoY to $361M, beating the high end of guidance by $6M.
- Core advertising revenue is stagnating: services ads up 1%, RR&O ads down 11%.
- Paying ad locations declined 6% YoY to 485,000, reflecting weak local demand.
- +12 more takeaways
Cherry Hill Mortgage Investment Corporation Q1 2026 Earnings Call - Geopolitical Shock Drives Volatility, Book Value Falls 6.1%, but Hedging and MSR Resilience Hold the Line
Cherry Hill Mortgage Investment Corporation navigated a turbulent first quarter of 2026, marked by a sudden geopolitical escalation involving Iran that spiked oil and gas prices, pushed inflation expe...
- Geopolitical shock from Iran conflict in March 2026 triggered sharp spikes in oil, gas, and inflation expectations, abruptly ending near-term rate cut expectations and widening mortgage spreads.
- Book value per common share fell 6.1% to $3.23, with economic return of -3.2% and GAAP net loss of $0.05 per diluted share, though EAD remained positive at $0.14 per share.
- Proactive interest rate hedging in March mitigated book value erosion, with a $396 million notional derivative portfolio (swaps, TBAs, Treasury futures, SOFR futures) effectively offsetting rate risk.
- +7 more takeaways
Karat Packaging Q1 2026 Earnings Call - Tariff Savings and Online Growth Offset Margin Pressure
Karat Packaging delivered a strong start to 2026 with Q1 sales up 13% year-over-year, driven by robust online growth and accelerating demand. The company navigated significant tariff headwinds and ris...
- Q1 2026 net sales reached $116.9 million, up 12.9% year-over-year, with momentum accelerating to over 20% growth in March.
- Online sales grew nearly 10% to $19.5 million, reflecting a successful strategic pivot to direct fulfillment and third-party digital platforms.
- Gross margin contracted to 35.5% from 39.3% in the prior year quarter, primarily due to higher import duties and tariffs.
- +9 more takeaways
The RealReal Q1 2026 Earnings Call - Resale Flywheel Accelerates as AI-Driven Margins Expand
The RealReal delivered a robust Q1 2026, marking its fourth consecutive quarter of double-digit top-line growth with GMV up 24% year-over-year to $606 million and revenue rising 19% to $190 million. T...
- GMV surged 24% to $606 million and revenue rose 19% to $190 million, marking the fourth straight quarter of double-digit growth.
- Adjusted EBITDA margin expanded 430 basis points year-over-year to 6.9%, with full-year guidance raised to $59–$67 million.
- Trailing 12-month active buyers grew 10% year-over-year, signaling accelerating engagement and platform trust.
- +17 more takeaways
Nature's Sunshine Products Q1 2026 Earnings Call - Digital Autoship Fuels Record Sales Growth
Nature's Sunshine delivered a record first quarter with sales rising 9% to $122.9 million and adjusted EBITDA jumping 33% to $14.6 million. The growth was led by a 42% surge in digital sales, driven b...
- Record Q1 2026 net sales of $122.9 million, up 9% year-over-year, marking the strongest first quarter in company history.
- Adjusted EBITDA surged 33% to $14.6 million, driven by sales growth and an 116 basis point expansion in gross margin to 73.2%.
- Digital sales jumped 42%, fueled by a 60% increase in new customers and robust adoption of the autoship subscription program, which now represents 48% of digital revenue.
- +7 more takeaways
CytomX Therapeutics Q1 2026 Earnings Call - Varseta-M Hits 32% Response Rate in Colorectal Cancer, Cash Runway Extends to 2028
CytomX Therapeutics delivered a strong start to 2026, anchored by clinical momentum in its lead asset, Varseta-M, a first-in-class EpCAM-directed antibody drug conjugate for metastatic colorectal canc...
- Varseta-M demonstrates transformative efficacy in late-line metastatic colorectal cancer, with a confirmed overall response rate of 20% to 32% and 7 months of median progression-free survival.
- Dose optimization enrollment is complete with 40 patients across 8.6 and 10 mg/kg doses, bringing total Phase I enrollment to 113 patients.
- CytomX aims to advance Varseta-M into a registrational study in late-line CRC in the first half of 2027, with a comprehensive Phase I data update expected in the second half of 2026.
- +7 more takeaways
Consensus Cloud Solutions Q1 2026 Earnings Call - Corporate Channel Accelerates Past 8% Growth
Consensus Cloud Solutions delivered a Q1 2026 quarter that validated its strategic pivot toward high-value corporate accounts, with corporate revenue surging 8.2% year-over-year to a record $58.7 mill...
- Corporate channel revenue hit a record $58.7 million, up 8.2% year-over-year, marking the strongest growth rate since Q4 2022 and validating the company’s strategic focus on high-value enterprise accounts.
- This marks the second consecutive quarter of year-over-year growth in all four key financial metrics: revenue, adjusted EBITDA, non-GAAP EPS, and free cash flow.
- Net revenue retention (NRR) rose to 102%, a 76 basis point sequential improvement, driven by deeper enterprise adoption and increased data volume routing through the platform.
- +9 more takeaways
Nektar Therapeutics Q1 2026 Earnings Call - REZPEG Advances to Phase III with $1B+ Cash Runway
Nektar Therapeutics is moving its lead candidate, REZPEG, into Phase III trials for atopic dermatitis (ZENITH-AD program) starting in July 2026, with first data expected mid-2028 and a BLA submission ...
- 1. Nektar Therapeutics is initiating the ZENITH-AD Phase III program for atopic dermatitis in July 2026, with first data expected mid-2028 and a BLA submission targeted for 2029.
- 2. The company plans to launch a Phase III study for alopecia areata in early 2027, aiming to add a second indication to the same BLA submission.
- 3. REZPEG’s novel regulatory T-cell mechanism shows deepening efficacy over time, with potential for monthly or quarterly maintenance dosing in atopic dermatitis.
- +9 more takeaways
SoundHound AI Q1 2026 Earnings Call - Accelerating Growth with LivePerson Acquisition and OASYS Platform Launch
SoundHound AI delivered strong Q1 2026 results with 52% year-over-year revenue growth to $44.2 million, driven by enterprise momentum and a 50%+ organic growth rate in its automotive and IoT segments....
- Q1 2026 revenue reached $44.2 million, up 52% year-over-year, with 50%+ organic growth excluding acquisitions.
- Management announced the acquisition of LivePerson, targeting a combined $500 million revenue opportunity from existing customer bases.
- OASYS platform launched, enabling AI to autonomously build, deploy, and refine agents across multiple channels.
- +12 more takeaways